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Background
The clinical utility of genotype-guided (pharmacogenetically based) dosing of war-
farin has been tested only in small clinical trials or observational studies, with 
equivocal results.
Methods
We randomly assigned 1015 patients to receive doses of warfarin during the first 
5 days of therapy that were determined according to a dosing algorithm that in-
cluded both clinical variables and genotype data or to one that included clinical 
variables only. All patients and clinicians were unaware of the dose of warfarin 
during the first 4 weeks of therapy. The primary outcome was the percentage of 
time that the international normalized ratio (INR) was in the therapeutic range 
from day 4 or 5 through day 28 of therapy.
Results
At 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the 
genotype-guided group and 45.4% in the clinically guided group (adjusted mean dif-
ference, [genotype-guided group minus clinically guided group], −0.2; 95% confi-
dence interval, −3.4 to 3.1; P = 0.91). There also was no significant between-group dif-
ference among patients with a predicted dose difference between the two algorithms 
of 1 mg per day or more. There was, however, a significant interaction between dosing 
strategy and race (P = 0.003). Among black patients, the mean percentage of time in the 
therapeutic range was less in the genotype-guided group than in the clinically guided 
group. The rates of the combined outcome of any INR of 4 or more, major bleeding, 
or thromboembolism did not differ significantly according to dosing strategy.
Conclusions
Genotype-guided dosing of warfarin did not improve anticoagulation control dur-
ing the first 4 weeks of therapy. (Funded by the National Heart, Lung, and Blood 
Institute and others; COAG ClinicalTrials.gov number, NCT00839657.)
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The need for clinical trials before widespread adoption of genotype-guided drug dosing and selection remains widely 
debated.1-4 Warfarin therapy has served as a 
model for the potential for pharmacogenetics to 
improve patient care.1 Observational studies have 
identified two genes, CYP2C9 and VKORC1, that 
are associated with variation in warfarin main-
tenance doses. However, the clinical utility of 
starting warfarin at the maintenance dose pre-
dicted by genotype-guided algorithms has been 
tested only in small trials, none of which were 
definitive.5-8 In contrast, observational studies 
have suggested potential benefits from geno-
type-guided dosing.9,10 In addition, previous 
clinical trials could not determine the usefulness 
of current dosing algorithms among black pa-
tients, for whom genotype-guided algorithms 
perform less well than for other populations.11-13
On the basis of available data, the Food and 
Drug Administration (FDA) has updated the la-
bel for warfarin twice, suggesting that variants 
in CYP2C9 and VKORC1 may be taken into consid-
eration when choosing the initial warfarin dose. 
However, the Centers for Medicare and Medicaid 
Services did not find sufficient evidence to cover 
the cost of genotyping for warfarin dosing.14 
Our study, called the Clarification of Optimal 
Anticoagulation through Genetics (COAG) trial, 
was designed to test the effect of genotype-
guided dosing on anticoagulation control.
Me thods
Study Design and Oversight
The COAG trial was a multicenter, double-blind, 
randomized, controlled trial that compared a 
genotype-guided warfarin-dosing strategy with a 
clinically based dosing strategy during the first 
5 days of therapy among patients initiating war-
farin treatment.15-17 The study was designed by the 
authors and approved by the institutional review 
board at the University of Pennsylvania and at 
each participating clinical center. The data were 
collected, analyzed, and interpreted by the au-
thors. A steering committee provided oversight 
of the trial (for details, see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org). An independent data and 
safety monitoring board monitored the trial and 
made recommendations to the National Heart, 
Lung, and Blood Institute. The first two authors 
wrote the first draft of the manuscript, which 
was edited and approved by all the authors.
The National Heart, Lung, and Blood Insti-
tute supported this study. Bristol-Myers Squibb 
donated Coumadin (warfarin). GenMark Diag-
nostics and AutoGenomics loaned genotyping 
platforms to the clinical centers. None of the 
companies supporting the trial had any role in 
the design of the protocol or in the collection, 
analysis, or interpretation of the data. The au-
thors vouch for the data and the analyses, and 
for the fidelity of this report to the trial proto-
col, which is available at NEJM.org.
Study Patients and Randomization
From September 2009 through April 2013, we 
enrolled both inpatients and outpatients at 18 
clinical centers in the United States. All the pa-
tients were adults initiating warfarin therapy 
with a target international normalized ratio 
(INR) of 2 to 3. Detailed inclusion and exclusion 
criteria are provided in the Supplementary Ap-
pendix. All patients provided written informed 
consent.
Patients were randomly assigned, in a 1:1 ra-
tio, to the use of a dosing algorithm that in-
cluded both clinical variables and genotype data 
or to a clinically guided dosing strategy. Ran-
domization was stratified according to clinical 
center and self-reported race (black vs. nonblack).
Genotyping for CYP2C9 and VKORC1 at each 
clinical center was performed with the use of 
one of two FDA-approved platforms, the Gen-
Mark Dx eSensor XT-8 or the AutoGenomics 
INFINITI Analyzer. Per protocol, genotyping 
was performed in all patients immediately after 
blood-sample collection to maintain blinding to 
the treatment assignment. Genotyping was re-
peated at the central laboratory with the use of 
either pyrosequencing or real-time polymerase-
chain-reaction assay to measure the accuracy at 
clinical centers.
Study Intervention and Follow-up
The study intervention period was the first 5 days 
of warfarin therapy. During this period, the pre-
specified algorithms were used to determine the 
warfarin dose. For each dosing strategy, a dose-
initiation algorithm was used during the first 
3 days of therapy, and a dose-revision algorithm 
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was used on day 4, 5, or both. The algorithms for 
the genotype-guided dosing strategy12,18 included 
clinical variables and genotype data for CYP2C9*2, 
CYP2C9*3, and VKORC1. The algorithms for the 
clinically based dosing strategy included clinical 
variables only. The dosing algorithms are pro-
vided in the Supplementary Appendix. If geno-
type information was not available for a patient 
in the genotype-guided dosing group before the 
administration of warfarin on any given day in 
the first 5 days, the clinical algorithm was used 
on that day.
During the first 4 weeks of therapy, patients 
and clinicians were unaware of the actual dose 
of warfarin that was administered, because the 
pills were encapsulated to prevent identification 
of the dose (see the Supplementary Appendix). 
After the 5-day initiation period, we adjusted the 
dose during the first 4 weeks using standardized 
dose-adjustment techniques,5,10 starting with the 
doses predicted by the algorithms and making 
the same relative adjustments on the basis of the 
INR in the two study groups. Clinicians were 
informed of the relative dose change (e.g., a 10% 
dose increase) at each INR measurement but not 
the actual dose of warfarin. Clinicians could 
contact the medical monitor (who was aware of 
the study-group assignments) to request an over-
ride of these relative dose changes without being 
informed of the actual dose. All patients were to 
be followed for a total of 6 months.
Study Outcomes
The primary outcome was the percentage of time 
in the therapeutic range (INR, 2 to 3) from the 
completion of the intervention period (day 4 or 5) 
through day 28 of therapy. We calculated the per-
centage of time in the therapeutic range using a 
standard linear interpolation method between 
successive INR values,19 as detailed in the Sup-
plementary Appendix. Each clinical center mea-
sured INRs with the use of instruments certified 
by the Clinical Laboratory Improvement Amend-
ments and following strict quality assurance.
Secondary outcomes included a composite 
outcome of any INR of 4 or more, major bleeding, 
or thromboembolism in the first 4 weeks (principal 
secondary outcome); the time to the first thera-
peutic INR; the time to the determination of a 
maintenance dose (which was defined as the 
time to the first of two consecutive INR mea-
surements, measured at least 1 week apart, that 
were in the therapeutic range without a dose 
change); and the time to an adverse event (death 
from any cause, major bleeding, thromboembo-
lism, or any clinically relevant nonmajor bleeding 
event20,21) in the first 4 weeks. Two physicians 
who were unaware of the study-group assign-
ments adjudicated major bleeding and thrombo-
embolic serious adverse events. The definitions 
of major bleeding,22 clinically relevant nonmajor 
bleeding, and thromboembolism are provided in 
the Supplementary Appendix.
Statistical Analysis
We analyzed the primary outcome in the modi-
fied intention-to-treat population, which includ-
ed all patients who underwent randomization 
with the exception of patients for whom INR 
data were not available (Fig. S1 in the Supple-
mentary Appendix). Safety outcomes were ana-
lyzed in the entire cohort, regardless of whether 
patients received the study drug. We used regres-
sion models to analyze the primary and secondary 
outcomes, using linear regression for the per-
centage of time in the therapeutic range and Cox 
regression for time-to-event outcomes. The pro-
tocol specified that we conduct coprimary analy-
ses in which we evaluated the primary outcome 
in all patients and in a primary subgroup, which 
comprised patients who had an absolute differ-
ence of 1.0 mg or more in the predicted initial 
daily dose between the genotype-guided dosing 
algorithm and the clinical dosing algorithm. We 
used an alpha allocation approach, which for-
mally allows for the evaluation of the treatment 
benefit in an enriched subgroup as a coprimary 
end point. In this approach, the overall type I er-
ror rate of 0.05 for the primary outcome was split 
between the analyses performed among all pa-
tients and among those in the primary sub-
group.17 All models were adjusted for the strati-
fication variables (center and race). Additional 
subgroups, which were prespecified, were race 
(black vs. nonblack), sex, and the total number of 
allelic variants (1 variant vs. 0 or >1 variant in 
either CYP2C9 or VKORC15). All statistical tests 
were two-sided. All analyses were performed 
with the use of the R statistical package, version 
3.0.1 (R Development Core Team).
We specified a minimum detectable difference 
of 5.5% in the mean percentage of time in the 
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therapeutic range between the genotype-guided 
group and the clinically guided group in the entire 
study population.16 We assumed a standard de-
viation for the percentage of time in therapeutic 
range of 25% and a potential dropout rate of 
10%. On the basis of recruitment rates,15 the 
initial sample size of 1238 patients was revised 
to 1022 patients on September 16, 2012 (with 








Median age (IQR) — yr† 59 (48–70) 57 (46–68)
Male sex — no. (%) 272 (53) 246 (49)
Race or ethnic group — no. (%)‡
Black† 141 (27) 134 (27)
Hispanic 32 (6) 33 (7)
Education — no. (%)
Did not complete high school 52 (10) 44 (9)
High-school diploma only 131 (25) 133 (27)
Post-secondary education 308 (60) 291 (58)
Did not respond 23 (4) 33 (7)
Current smoker — no. (%)† 77 (15) 68 (14)
Median body-surface area (IQR)  — m2† 2.01 (1.83–2.19) 2.03 (1.85–2.23)
Warfarin and other therapies — no. (%)
Inpatient warfarin initiation 348 (68) 332 (66)
Indication for warfarin therapy
Deep-vein thrombosis or pulmonary embolism only 289 (56) 300 (60)
Atrial fibrillation or flutter only 116 (23) 105 (21)
Other indication only 56 (11) 53 (11)
Multiple indications 49 (10) 39 (8)
No indication given 4 (1) 4 (1)
Deep-vein thrombosis or pulmonary embolism as primary 
indication†
305 (59) 317 (63)
Expected duration of warfarin therapy
<1 mo 33 (6) 33 (7)
1–3 mo 35 (7) 30 (6)
>3 mo 446 (87) 438 (87)
Previous warfarin use 38 (7) 48 (10)
Current amiodarone use† 13 (3) 10 (2)
Current fluvastatin use† 2 (<1) 1 (<1)
Current heparin use 278 (54) 281 (56)
Medical history — no. (%)
Congestive heart failure 63 (12) 64 (13)
Deep-vein thrombosis 149 (29) 146 (29)
Diabetes† 118 (23) 121 (24)
Hypertension 280 (54) 260 (52)
Myocardial infarction 47 (9) 48 (10)
Pulmonary embolism 109 (21) 105 (21)
Stroke† 37 (7) 31 (6)
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the approval of the data and safety monitoring 
board). The revised sample size provided a 
power of at least 80% to detect a between-group 
difference of 5.5% at a type I error rate of 0.04 
among all patients  and a 9.0% difference at a 
type I error rate of 0.01 among patients in the 
coprimary analysis.
R esult s
Patients, Genotyping, and Follow-up
A total of 1015 patients were enrolled and ran-
domly assigned to either the genotype-guided 
dosing algorithm or the clinically guided dosing 
algorithm (Fig. S1 in the Supplementary Appen-
dix). There were no significant between-group 
differences at baseline (Table 1). The characteris-
tics of the patients according to self-reported 
race are provided in Table S1 in the Supplemen-
tary Appendix. A total of 60 participants (30 in 
each group) withdrew before completing the in-
tervention period and did not have an available 
percentage of time in the therapeutic range, re-
sulting in an analytic sample size of 955. A me-
dian of six INRs were measured during the first 
4 weeks in each of the two study groups. Dis-
pensed doses during the intervention period are 
summarized in Table S2 in the Supplementary 
Appendix.
Genotype data were available in the geno-
type-guided group for 45% of the patients before 
the first warfarin dose, for 94% before the sec-
ond warfarin dose, and for 99% before the ap-
plication of the dose-revision algorithm on day 4 
or 5. The mean (±SD) difference between the 









Genetic variants — no. (%)
CYP2C9*2†
No variants 414 (81) 423 (84)
Heterozygous 92 (18) 70 (14)
Homozygous 4 (1) 7 (1)
Withdrew before genotyping 4 (1) 1 (<1)
CYP2C9*3†
No variants 471 (92) 451 (90)
Heterozygous 38 (7) 49 (10)
Homozygous 1 (<1) 0
Withdrew before genotyping 4 (1) 1 (<1)
VKORC1 (VKORC1 3673G→A)†
No variants (GG) 250 (49) 237 (47)
Heterozygous (AG or GA) 201 (39) 202 (40)
Homozygous (AA) 59 (11) 61 (12)
Withdrew before genotyping 4 (1) 1 (<1)
Total no. of variants§
0 204 (40) 189 (38)
1 178 (35) 186 (37)
>1 128 (25) 125 (25)
Withdrew before genotyping 4 (1) 1 (<1)
* There were no significant between-group differences for any characteristic. IQR denotes interquartile range.
† This variable was used in the algorithms for dose initiation and dose revision in the two study groups. Dosing algo-
rithms are provided in the Supplementary Appendix.
‡ Race or ethnic group was self-reported.
§ The total number of variants was defined as the number of measured variants in CYP2C9*2, CYP2C9*3, and VKORC1.
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data on day 1, as compared with the dose they 
would have received if genotype data had been 
available, was −0.1±0.4 mg per day during the 
first 3 days. The central laboratory confirmed 
99.8% of all genotyping results from the clinical 
centers. All genotype distributions were in Hardy–
Weinberg equilibrium (P>0.20 for all comparisons).
Primary Outcome
At 4 weeks, there was no significant between-
group difference in the mean percentage of time 
in the therapeutic range: 45.2% in the genotype-
guided group and 45.4% in the clinically guided 
group (adjusted mean difference [genotype-
guided group minus clinically guided group], 
−0.2%; 95% confidence interval, −3.4 to 3.1; 
P = 0.91) (Table 2 and Fig. 1). There was also no 
significant between-group difference in the per-
centage of time in the therapeutic range among 
patients in the coprimary analysis (Table 2). 
When the 4-week trial was divided into two 
2-week intervals, there was also no significant 
difference between the groups in either interval 
(Table 2).
However, there was  a significant interaction 
between race and dosing strategy (P = 0.003) 
(Table 2). Among black patients, the mean per-
centage of time in the therapeutic range was 









(95% CI) † P Value
percent percentage point
Primary analyses 955
All patients 45.2±26.6 45.4±25.8 −0.2 (−3.4 to 3.1) 0.91‡
Patients stratified by absolute dif fer ence 
between algorithms in predicted 
dose
0.63 ¶
≥1.0 mg/day§ 392 45.1±25.5 46.5±27.1 −1.1 (−6.2 to 4.0) 0.67‖
<1.0 mg/day 563 45.2±27.4 44.7±24.8 0.5 (−3.7 to 4.8) 0.81
Prespecified subgroup analyses
Race 0.003¶
Black 255 35.2±26.0 43.5±26.5 −8.3 (−15.0 to −2.0) 0.01
Nonblack 700 48.8±25.9 46.1±25.5 2.8 (−1.0 to 6.6) 0.15
Sex 0.71¶
Male 486 44.9±26.9 45.5±25.4 0.4 (−4.2 to 5.1) 0.85
Female 469 45.4±26.3 45.3±26.2 −0.8 (−5.5 to 3.9) 0.73
Total no. of genetic variants ** 0.21¶
1 343 48.1±26.5 45.0±23.7 2.6 (−2.9 to 8.1) 0.35
0 or >1 variant 612 43.6±26.5 45.7±27.0 −1.7 (−5.8 to 2.4) 0.41
Analysis according to 2-wk intervals
From day 4 or 5 to day 14 935 40.3±28.3 40.3±27.3 0.1 (−3.4 to 3.6) 0.96
From day 15 to day 28 913 59.9±36.6 59.9±36.3 0.0 (−4.8 to 4.7) 0.99
* Plus–minus values are means ±SD. CI denotes confidence interval.
† Values are the mean difference in the percentage of time in the therapeutic INR range in the genotype-guided group 
as compared with the clinically guided group, as estimated from multivariable linear regression models and adjusted 
for race and clinical center. A positive value indicates more time in the therapeutic range in the genotype-guided group.
‡ The type I error rate was fixed at 0.04.
§ Patients who had an absolute difference of 1.0 mg or more in the predicted initial daily dose between the genotype-guided 
dose-initiation algorithm and the clinically guided dose-initiation algorithm were designated as the coprimary analysis group.
¶ The P value for interaction was calculated to evaluate the equality of the mean difference between subgroups.
‖ The type I error rate was calculated to be 0.016 on the basis of the alpha allocation approach.17
** The total number of genetic variants was defined as the number of measured variants in CYP2C9*2, CYP2C9*3, and 
VKORC1.
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less in the genotype-guided group than in the 
clinically guided group (35.2% vs. 43.5%; ad-
justed mean difference, −8.3%; P = 0.01). Among 
nonblack patients, the mean percentage of time 
in the therapeutic range was slightly higher in 
the genotype-guided group than in the clinically 
guided group (48.8% vs. 46.1%; adjusted mean 
difference, 2.8%; P = 0.15). There were no signifi-
cant differences in the percentage of time in the 
therapeutic range according to sex or the total 
number of genetic variants (Table 2).
Anticoagulation Control and Dose 
Prediction
There were no significant between-group differ-
ences in the mean percentage of time above the 
therapeutic range (INR, >3) or below the thera-
peutic range (INR, <2) (Fig. 2, and Table S3 in 
the Supplementary Appendix). However, black 
patients in the genotype-guided group were more 
likely to have INRs above the therapeutic range 
than were those in the clinically guided group 
(Fig. S2 and Table S3 in the Supplementary Ap-
pendix).
There was no overall between-group difference 
in the time to the first INR in the therapeutic 
range (Table S4 in the Supplementary Appendix). 
However, black patients in the genotype-guided 
group took longer on average to reach the first 
therapeutic INR than did those in the clinically 
guided group (Table S4 and Fig. S3 in the Sup-
plementary Appendix). The time to the determi-
nation of the maintenance dose did not differ 















































Figure 1. Distribution of Time in the Therapeutic Range.
Side-by-side density plots show the distribution of the percentage of time in the therapeutic range of the international 
normalized ratio (INR) from the completion of the intervention period (day 4 or 5) to day 28 of therapy for the two 
study groups among all patients (at left), among patients stratified according to the absolute difference in the pre-
dicted initial daily dose of warfarin between the two algorithms (≥1 mg [primary subgroup] vs. <1 mg) (at top right), 
and among patients stratified according to race (at bottom right). The horizontal lines indicate the mean percentage 
of time in the therapeutic range.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;24 nejm.org december 12, 20132290
according to the primary subgroup, race, or total 
number of genetic variants (Table S5 in the 
Supplementary Appendix).
The performance characteristics of the dos-
ing algorithms with respect to the maintenance 
dose that was determined are shown in Table S6 
(which includes the accuracy of a hypothetical, 
empirical dosing strategy of 5 mg per day) and 
in Figure S4, both in the Supplementary Appen-
dix. The genotype-guided algorithms performed 
better at predicting the maintenance dose among 
nonblack patients than among black patients. 
Dose overrides during the first 4 weeks were 
rare, occurring in only 3.9% of doses in the 
genotype-guided group and 3.6% of those in 
the clinically guided group; rates of overrides 
did not differ according to race.
Adverse Events
At 4 weeks, there were no significant between-
group differences in the principal secondary out-
come (the time to any INR of ≥4, major bleeding, 
or thromboembolism) or any other adverse 
events (Table 3, and Table S7 in the Supplemen-
tary Appendix). Safety data for the entire dura-
tion of follow-up (i.e., past the primary outcome 
duration) are provided in Table S8 in the Supple-
mentary Appendix.
Discussion
In our study, we found no benefit of genotype-
guided dosing of warfarin with respect to the pri-
mary outcome of the percentage of time in the 
therapeutic INR range, either overall or among 
patients with a predicted dose difference between 
the genotype-guided algorithm and the clinically 
guided algorithm of at least 1 mg per day. Our 
findings exclude a meaningful effect of genotype-
guided dosing on the percentage of time in the 
therapeutic range during the first month of 
warfarin treatment. How ever, there was a sig-
nificant difference in the effects of the algo-
rithms in the prespecified subgroup of black 
patients, as compared with nonblack patients. 
Although the interaction between race and dos-
ing strategy with respect to the primary out-
come could be due to chance, the analysis was 
prespecified and was consistent with our a pri-
ori hypothesis that there would be race-based 
differences.
The dosing algorithms that we used in the 
trial have been validated and account for race 
(specifically black vs. nonblack).11-13,18 The gen-
otype-guided algorithm performed as well as 
anticipated on the basis of previous stud-
ies,5,8,10-12,18,23 with an R2 of 0.48 and a mean 
absolute error of 1.3 mg per day for the dose-
initiation algorithm and an R2 of 0.69 and a 
mean absolute error of 1.0 mg per day for the 
dose-revision algorithm. Despite this accuracy in 
predicting maintenance doses, there was no 
benefit of genotype-guided dosing with respect 
to anticoagulation control.
Observational studies have shown an associa-
tion between the use of genetic algorithms and 
improved outcomes, but because of limitations 
in the study design, they were unable to assess 
whether the observed associations were causal.1,9,10 
Previous clinical trials have produced equivocal 
results,5-8 but these trials were limited by a small 
size and lack of blinding to the warfarin dose. 
The two trials that suggested possible benefit 
also were limited by large numbers of dropouts6 
and a comparison with nonalgorithm-based 
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Figure 2. Range of INRs during the 4-Week Study.
Shown are the INRs from the completion of the intervention period (day 4 
or 5) to day 28 of therapy in the two study groups. Solid lines represent 
smoothing splines with 5 degrees of freedom. Dashed lines represent the 
20th and 80th percentiles of INR values calculated over a 3-day window.
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black patients6-8 or a minimal number of black 
patients5 (a total of 3) (Anderson J: personal 
communication).
The average percentage of time in the thera-
peutic range of 45% in our study is similar to 
that in other trials, taking into account the 
range of INRs used for the calculation and the 
timing and duration of therapy (Tables S9A and 
S9B in the Supplementary Appendix).5,10,24,25 Un-
like previous trials that used only a baseline 
genotype-guided algorithm, our study used both 
a dose-initiation and a dose-revision algorithm. 
A recent study comparing a similar initiation 
algorithm with a combined initiation and revi-
sion algorithm showed no effect on the percent-
age of time in the therapeutic range with the 
addition of the revision algorithm.10
There are several questions that our study was 
not designed to answer. First, the trial did not 
compare genotype-based dosing with usual care 
or a fixed initial dose (e.g., 5 mg per day). How-
ever, such a comparison could not have dis-
cerned whether differences in outcomes were 
due to the marginal benefit of genetic informa-
tion or to the use of the clinical information that 
is included in all genotype-guided dosing algo-
rithms. Second, our study does not address the 
question of whether a longer duration of geno-
type-guided dosing would have improved INR 
control,26 an issue that is being addressed in 
another trial.27 Third, the dosing algorithms 
that we used included the three single-nucleotide 
polymorphisms among the two genes that are 
most likely to influence warfarin dosing. Al-
though other genes may contribute to warfarin 
dosing, it is unlikely that they have a substantial 
effect, particularly in white populations.28 
Fourth, although there were no significant be-
tween-group differences in the rates of bleeding 
or thromboembolic events during the primary 
follow-up period of 4 weeks, the trial was not 
powered for these outcomes. Fifth, the first dose 
of warfarin was not informed by genotyping in 
55% of the patients; whether this influenced the 
results is unknown. However, the effect of missing 
genetics data on day 1 on the dose administered 
during the first 3 days of therapy was trivial.
In conclusion, our findings do not support 
the hypothesis that initiating warfarin therapy at 
a genotype-guided maintenance dose for the 
first 5 days, as compared with initiating warfa-
rin at a clinically predicted maintenance dose, 








Hazard Ratio  
(95% CI)* P Value
no. (%)
Any INR ≥4, major bleeding, or 
thromboembolism†
105 (20) 103 (21) 1.01 (0.77–1.33) 0.93
Any INR ≥4 100 (19) 92 (18) 1.08 (0.81–1.44) 0.59
Major bleeding‡ 4 (1) 10 (2) 0.41 (0.13–1.31) 0.13
Thromboembolism 5 (1) 4 (1) 1.27 (0.34–4.73) 0.72
Clinically relevant nonmajor bleeding§ 13 (3) 20 (4) 0.62 (0.30–1.27)§ 0.18
Death from any cause 2 (<1) 1 (<1) 2.09 (0.19–23.22) 0.55
* Hazard ratios are for the comparison between the genotype-guided dosing group and the clinically guided dosing 
group, as estimated from multivariable Cox regression models and adjusted for race and clinical center. A hazard ratio 
of more than 1 indicates that patients in the genotype-guided had, on average, a shorter time to an adverse event than 
did those in the clinically guided dosing group. Follow-up time began at randomization. Censoring events for major 
bleeding and thromboembolic events were death and administrative censoring at day 28. The censoring event for death 
was administrative censoring at day 28.
† This composite was the principal secondary outcome.
‡ The INR at the time of the bleeding event was available for all but one patient (in the clinically guided dosing group). 
The INR was elevated (>3) in three patients in the genotype-guided dosing group and in one patient in the clinically 
guided dosing group.
§ The binary outcome of any clinically relevant nonmajor bleeding event was analyzed with the use of a multivariable lo-
gistic-regression model, adjusted for race and clinical enter. The point estimate and confidence interval are estimated 
odds ratios for a clinically relevant nonmajor bleeding event in the genotype-guided group as compared with the clini-
cally guided group.
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improves anticoagulation control during the 
first 4 weeks of therapy. Our results emphasize 
the importance of performing randomized trials 
for pharmacogenetics, particularly for complex 
regimens such as warfarin.
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